Shiaw-Yih Lin

8PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 29, 2026
Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.

|Apr 13, 2026
Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.

Camilla O Hoff, Simon Heeke, Yoshitsugu Mitani

|Jan 07, 2026
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Sarah K Herzog, Jessica H Stevens, Guowei Gu

|Jan 03, 2024
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.

Mei Zhao, Tianxiao Wang, Frederico O Gleber-Netto

|May 31, 2023
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.

Luana Guimaraes Sousa, Daniel J McGrail, Felippe Lazar Neto

|Oct 27, 2021
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

Daniel J McGrail, Patrick G Pilié, Hui Dai

Pageof 2

Frequent Collaborators

5 joint publications

Daniel J McGrail

2 joint publications

Yoshitsugu Mitani

2 joint publications

Renata Ferrarotto

2 joint publications

Hui Dai